Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.58 Insider Own19.40% Shs Outstand48.08M Perf Week-17.63%
Market Cap150.55M Forward P/E- EPS next Y-1.77 Insider Trans0.92% Shs Float38.77M Perf Month22.50%
Income-123.46M PEG- EPS next Q-0.54 Inst Own54.69% Short Float14.41% Perf Quarter29.88%
Sales0.00M P/S- EPS this Y25.09% Inst Trans11.56% Short Ratio10.79 Perf Half Y71.04%
Book/sh1.47 P/B2.13 EPS next Y8.17% ROA-71.49% Short Interest5.59M Perf Year-5.44%
Cash/sh2.32 P/C1.35 EPS next 5Y- ROE-98.37% 52W Range1.24 - 4.07 Perf YTD27.24%
Dividend Est.- P/FCF- EPS past 5Y-25.30% ROI-172.65% 52W High-23.06% Beta1.06
Dividend TTM- Quick Ratio4.11 Sales past 5Y-56.91% Gross Margin- 52W Low152.42% ATR (14)0.31
Dividend Ex-Date- Current Ratio4.11 EPS Y/Y TTM5.54% Oper. Margin0.00% RSI (14)50.43 Volatility8.84% 10.42%
Employees65 Debt/Eq0.03 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price11.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q10.43% Payout- Rel Volume0.94 Prev Close3.35
Sales Surprise- EPS Surprise29.34% Sales Q/Q- EarningsMar 26 AMC Avg Volume517.68K Price3.13
SMA201.96% SMA5012.86% SMA20034.46% Trades Volume485,619 Change-6.57%
Date Action Analyst Rating Change Price Target Change
Sep-15-22Initiated JMP Securities Mkt Outperform $17
May-05-22Downgrade Credit Suisse Outperform → Neutral $35 → $5
Mar-21-22Initiated H.C. Wainwright Buy $25
Oct-15-21Resumed BTIG Research Buy $68
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jan-11-21Initiated Credit Suisse Outperform $49
Mar-27-24 10:07AM
Mar-26-24 09:54PM
08:00AM Loading…
Mar-19-24 08:00AM
Mar-07-24 08:00AM
Dec-20-23 08:00AM
Dec-13-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
Nov-07-23 04:01PM
04:05PM Loading…
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
Aug-02-23 11:31AM
Aug-01-23 04:01PM
Jul-25-23 08:00AM
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
09:29AM Loading…
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
Nov-08-22 08:00AM
Nov-04-22 11:15AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
Sep-12-22 10:08AM
Aug-18-22 06:39AM
Aug-09-22 07:25PM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jun-04-22 08:12AM
Jun-01-22 04:05PM
May-04-22 04:01PM
Apr-08-22 08:00AM
Mar-01-22 06:00AM
Feb-07-22 05:38PM
Jan-10-22 04:05PM
Dec-21-21 09:00AM
Dec-11-21 06:34AM
Nov-15-21 05:09PM
Oct-04-21 10:56AM
Sep-29-21 08:03AM
Sep-12-21 08:49AM
Aug-13-21 05:54PM
Jun-14-21 02:03AM
May-12-21 06:26PM
Mar-16-21 01:59AM
Dec-18-20 04:00PM
Dec-16-20 05:34PM
Dec-15-20 07:59PM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCBRINN SYLVIADirectorDec 26 '23Buy2.334,0009,32015,125Dec 26 07:43 PM
SHORT JAY M PHDChief Executive OfficerDec 20 '23Buy2.1450,000106,9101,439,283Dec 20 06:27 PM
STEINMAN LAWRENCEDirectorDec 19 '23Buy2.0520,00041,04838,459Dec 19 08:24 PM
Vasquez ChristianSee RemarksDec 19 '23Buy2.047,49515,262115,659Dec 19 04:33 PM
MCBRINN SYLVIADirectorSep 08 '23Buy2.542,0005,08011,125Sep 13 06:55 PM
Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
KTTA Pasithea Therapeutics Corp daily Stock Chart
Index- P/E- EPS (ttm)-13.31 Insider Own28.46% Shs Outstand1.04M Perf Week-12.24%
Market Cap7.76M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.75M Perf Month3.25%
Income-15.96M PEG- EPS next Q- Inst Own1.19% Short Float1.16% Perf Quarter-1.58%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio1.37 Perf Half Y-12.03%
Book/sh22.46 P/B0.33 EPS next Y- ROA-43.50% Short Interest0.01M Perf Year-6.16%
Cash/sh15.70 P/C0.48 EPS next 5Y- ROE-47.07% 52W Range5.25 - 17.40 Perf YTD0.81%
Dividend Est.- P/FCF- EPS past 5Y- ROI-68.22% 52W High-57.13% Beta0.86
Dividend TTM- Quick Ratio6.34 Sales past 5Y-33.33% Gross Margin- 52W Low41.99% ATR (14)0.48
Dividend Ex-Date- Current Ratio6.34 EPS Y/Y TTM-20.79% Oper. Margin0.00% RSI (14)48.30 Volatility5.18% 4.26%
Employees8 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-23.32% Payout- Rel Volume0.28 Prev Close7.65
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% Earnings- Avg Volume6.36K Price7.46
SMA20-0.47% SMA503.61% SMA200-12.35% Trades Volume1,782 Change-2.48%
Feb-13-24 07:59AM
Jan-08-24 07:59AM
Jan-02-24 08:35AM
Dec-28-23 05:00PM
Dec-19-23 05:19PM
09:03AM Loading…
Dec-13-23 09:03AM
Dec-11-23 11:18AM
Nov-29-23 04:27PM
Nov-09-23 07:59AM
Sep-14-23 08:30AM
Sep-07-23 04:14PM
Aug-01-23 07:59AM
Jul-31-23 06:00AM
08:43AM Loading…
Jul-20-23 08:43AM
Jul-13-23 09:14AM
Jun-30-23 09:28AM
Jun-29-23 02:50PM
Jun-06-23 04:30PM
Jun-05-23 09:00AM
Jun-01-23 07:57AM
May-14-23 08:13AM
May-03-23 08:26AM
Mar-02-23 08:00AM
Feb-23-23 08:00AM
Feb-16-23 07:30AM
Jan-18-23 08:00AM
05:18PM Loading…
Dec-14-22 05:18PM
Dec-12-22 07:00AM
Dec-07-22 04:00PM
Dec-06-22 08:00AM
Nov-28-22 07:05PM
Nov-22-22 04:00PM
Oct-27-22 09:50AM
Oct-17-22 08:00AM
Oct-14-22 09:48AM
Oct-13-22 04:00PM
Oct-12-22 08:00AM
Oct-10-22 09:39AM
Oct-03-22 06:03PM
Sep-28-22 09:00AM
Sep-20-22 08:00AM
Sep-15-22 08:00AM
Sep-12-22 11:53AM
Sep-09-22 10:32AM
Sep-06-22 09:30AM
Aug-24-22 08:00AM
Aug-18-22 08:00AM
Aug-11-22 08:00AM
Aug-05-22 09:00AM
Aug-02-22 07:00AM
Jul-14-22 08:00AM
Jun-23-22 09:00AM
Jun-22-22 08:00AM
Apr-14-22 04:15PM
Apr-05-22 03:57PM
Mar-30-22 04:15PM
Mar-08-22 08:00AM
Feb-24-22 08:00AM
Feb-09-22 08:00AM
Feb-03-22 08:00AM
Jan-26-22 08:00AM
Dec-23-21 11:35AM
Dec-21-21 08:00AM
Dec-01-21 08:00AM
Nov-29-21 05:45PM
Nov-24-21 08:52AM
Nov-23-21 11:39AM
Nov-17-21 08:00AM
Nov-11-21 08:00AM
Nov-09-21 08:00AM
Oct-27-21 11:40AM
Oct-18-21 01:37PM
Oct-14-21 09:13AM
Oct-11-21 10:08AM
Oct-05-21 08:37AM
Oct-04-21 08:00AM
Sep-29-21 04:30PM
Sep-20-21 12:51PM
Sep-17-21 04:05PM
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorJun 02 '23Buy0.4330,00012,9301,327,174Jun 06 09:00 PM
Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
ATNF 180 Life Sciences Corp daily Stock Chart
Index- P/E- EPS (ttm)-28.80 Insider Own3.20% Shs Outstand0.53M Perf Week-3.14%
Market Cap1.14M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.52M Perf Month-39.66%
Income-19.94M PEG- EPS next Q- Inst Own6.91% Short Float8.14% Perf Quarter-49.27%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.46 Perf Half Y-79.71%
Book/sh-0.24 P/B- EPS next Y- ROA-98.29% Short Interest0.04M Perf Year-90.68%
Cash/sh3.74 P/C0.58 EPS next 5Y- ROE-355.47% 52W Range1.80 - 27.93 Perf YTD-46.75%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-92.27% Beta-
Dividend TTM- Quick Ratio0.72 Sales past 5Y0.00% Gross Margin- 52W Low19.67% ATR (14)0.41
Dividend Ex-Date- Current Ratio0.72 EPS Y/Y TTM82.38% Oper. Margin0.00% RSI (14)38.16 Volatility12.84% 17.02%
Employees4 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price1520.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q78.93% Payout- Rel Volume0.23 Prev Close2.22
Sales Surprise- EPS Surprise84.62% Sales Q/Q- Earnings- Avg Volume92.62K Price2.16
SMA20-16.84% SMA50-34.52% SMA200-74.82% Trades Volume20,953 Change-2.70%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
Mar-14-24 08:30AM
Feb-26-24 07:00AM
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
08:46AM Loading…
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
08:00AM Loading…
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
08:30AM Loading…
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woody James N.Chief Executive OfficerDec 15 '23Buy0.1925,0004,70066,888Dec 18 04:15 PM
Feldmann MarcDirectorDec 15 '23Sale0.1925,0004,700115,497Dec 18 04:15 PM
STEINMAN LAWRENCEDirectorJun 01 '23Buy1.2318,00022,06848,129Jun 02 08:00 AM
McGovern Jr. Donald A.DirectorMay 31 '23Buy1.1510,00011,47030,099Jun 01 08:00 AM
McGovern Jr. Donald A.DirectorMay 19 '23Buy1.165,0005,80020,099May 22 08:00 AM
Woody James N.Chief Executive OfficerMay 18 '23Buy1.0340,00041,20041,888May 18 04:40 PM
McGovern Jr. Donald A.DirectorMay 18 '23Buy1.0510,00010,50015,099May 22 08:00 AM
Marrone Pamela GDirectorMay 18 '23Buy1.067,0827,50712,469May 19 08:45 AM
Pamir OzanCFOMay 18 '23Buy1.015,1625,2148,983May 19 08:30 AM